HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 54.71M
Enterprise Value 37.7M
Trailing P/E N/A
Forward P/E 1-0.43
PEG Ratio (5 yr expected) 1-0.01
Price/Sales (ttm)15.35
Price/Book (mrq)0.80
Enterprise Value/Revenue 325.07
Enterprise Value/EBITDA 6-0.70

Trading Information

Stock Price History

Beta (3Y Monthly) 1.59
52-Week Change 3-84.40%
S&P500 52-Week Change 30.90%
52 Week High 314.9600
52 Week Low 30.0000
50-Day Moving Average 32.7589
200-Day Moving Average 35.8033

Share Statistics

Avg Vol (3 month) 3172.49k
Avg Vol (10 day) 354.4k
Shares Outstanding 5251.49k
Float 2.03M
% Held by Insiders 112.78%
% Held by Institutions 16.09%
Shares Short (Jul 31, 2019) 4133.15k
Short Ratio (Jul 31, 2019) 41.16
Short % of Float (Jul 31, 2019) 48.77%
Short % of Shares Outstanding (Jul 31, 2019) 46.01%
Shares Short (prior month Jun 28, 2019) 4144.55k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 244/1
Last Split Date 3Jun 11, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-3,846.25%

Management Effectiveness

Return on Assets (ttm)-50.05%
Return on Equity (ttm)-128.89%

Income Statement

Revenue (ttm)307k
Revenue Per Share (ttm)0.23
Quarterly Revenue Growth (yoy)-12.10%
Gross Profit (ttm)-517k
EBITDA -11.03M
Net Income Avi to Common (ttm)-10.08M
Diluted EPS (ttm)-7.7020
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.86M
Total Cash Per Share (mrq)1.24
Total Debt (mrq)4.89M
Total Debt/Equity (mrq)74.63
Current Ratio (mrq)2.15
Book Value Per Share (mrq)2.40

Cash Flow Statement

Operating Cash Flow (ttm)-9.63M
Levered Free Cash Flow (ttm)-6.65M